Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1-2
|
| pubmed:dateCreated |
1997-9-26
|
| pubmed:abstractText |
The purpose of our study was to determine the efficacy of 2-chlorodeoxyadenosine (2-CdA) administered in 2-hour intravenous infusions in previously treated patients with low grade non-Hodgkin's lymphoma (LGNHL). We treated 94 LGNHL patients with 2-CdA at a dosage of 0.12 mg/kg/24h in 2-hour intravenous infusion for 5 consecutive days. The treatment consisted of from 1 to 7 courses (median 3), repeated usually at monthly intervals. All patients were refractory to or relapsed after standard chemotherapy. Of these 94 patients 78 (83%) had clinical stage IV of the disease. Complete response (CR) was obtained in 12 (12.8%) and partial response (PR) in 36 (38.3%) giving an overall response rate of 51.1%. In 12 (12.8%) grade 4 thrombocytopenia with haemorrhagic diathesis was noted, grade 4 neutropenia was observed in 12 (12.8%) and infections complicated the course of treatment in 38 (40.4%) patients. 2-CdA treatment was the cause of death of 3 patients. The results of our study show that 2-CdA given in 2-hour infusions is an effective agent in advanced, heavily pretreated patients with LGNHL.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1042-8194
|
| pubmed:author |
pubmed-author:Adamczyk-CiochM BMB,
pubmed-author:BoguradzkiPP,
pubmed-author:BorawskaAA,
pubmed-author:CeglarekBB,
pubmed-author:DerenMM,
pubmed-author:Dmoszy?skaAA,
pubmed-author:Dur?y?skiTT,
pubmed-author:Dwilewicz-TrojaczekJJ,
pubmed-author:Gora-TyborJJ,
pubmed-author:GriebPP,
pubmed-author:HellmannAA,
pubmed-author:KonopkaLL,
pubmed-author:KrykowskiEE,
pubmed-author:KuratowskaZZ,
pubmed-author:MajSS,
pubmed-author:MichalakKK,
pubmed-author:Opali?skaJJ,
pubmed-author:Plu?a?skaAA,
pubmed-author:PotemskiPP,
pubmed-author:RóbakTT,
pubmed-author:SikorskaAA,
pubmed-author:Urasi?skiJJ,
pubmed-author:WalewskiJ AJA,
pubmed-author:ZauchaJ MJM
|
| pubmed:issnType |
Print
|
| pubmed:volume |
26
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
99-105
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9250793-Adult,
pubmed-meshheading:9250793-Aged,
pubmed-meshheading:9250793-Antineoplastic Agents,
pubmed-meshheading:9250793-Cladribine,
pubmed-meshheading:9250793-Female,
pubmed-meshheading:9250793-Humans,
pubmed-meshheading:9250793-Infusions, Intravenous,
pubmed-meshheading:9250793-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9250793-Male,
pubmed-meshheading:9250793-Middle Aged,
pubmed-meshheading:9250793-Neoplasm Staging,
pubmed-meshheading:9250793-Retreatment
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
|
| pubmed:affiliation |
Department of Hematology, Medical University of Lód?, Poland.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|